JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Certara Inc

Затворен

СекторЗдравеопазване

6.17 0.82

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.12

Максимум

6.3

Ключови измерители

By Trading Economics

Приходи

-7.4M

-5.9M

Продажби

-968K

104M

P/E

Средно за сектора

100.714

67.147

Марж на печалбата

-5.688

Служители

1,515

EBITDA

8.6M

32M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+44.07% upside

Дивиденти

By Dow Jones

Следващи печалби

11.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-77M

957M

Предишно отваряне

5.35

Предишно затваряне

6.17

Настроения в новините

By Acuity

50%

50%

186 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Certara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 23:08 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 23:07 ч. UTC

Печалби

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:20 ч. UTC

Печалби

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Gains on Wall Street -- Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30.04.2026 г., 23:27 ч. UTC

Пазарно говорене

Liontown Lithium Recovery Expected to Improve -- Market Talk

30.04.2026 г., 23:22 ч. UTC

Печалби

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30.04.2026 г., 22:52 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:33 ч. UTC

Печалби

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30.04.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30.04.2026 г., 22:05 ч. UTC

Печалби

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 21:57 ч. UTC

Печалби

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30.04.2026 г., 21:55 ч. UTC

Печалби

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30.04.2026 г., 21:53 ч. UTC

Печалби

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение с други в отрасъла

Ценова промяна

Certara Inc Прогноза

Ценова цел

By TipRanks

44.07% нагоре

12-месечна прогноза

Среден 8.5 USD  44.07%

Висок 10 USD

Нисък 7 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Certara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

3

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

11.27 / 12.79Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Strong Bullish Evidence

Настроение

By Acuity

186 / 347 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat